This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the con ...

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDAGAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of ...

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference:Leerink Global Healthcare Conference Date/Time:Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About ...

The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn moreEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing g ...

Financial Performance - Altimmune reported a revenue of $20,000 for the year ended December 31, 2024, a decrease of 95% compared to $426,000 in 2023[492]. - The net loss for the year ended December 31, 2024, was $95,059,000, an increase of 7% from a net loss of $88,447,000 in 2023[492]. - Revenues for the year ended December 31, 2024, decreased to $20, down 95.3% from $426 in 2023[541]. - Net loss for 2024 was $95.1 million, compared to a net loss of $88.4 million in 2023, representing an increase of 7.5%[541]. - The net loss before income tax benefit for the year ended December 31, 2024 was $95.059 million, compared to $88.447 million for 2023[628]. Research and Development - Research and development expenses increased by 25% to $82,226,000 in 2024 from $65,799,000 in 2023, primarily driven by the ramp-up of the IMPACT Phase 2b trial[494]. - The development of the product candidate pemvidutide saw a 49% increase in expenses, totaling $53,274,000 in 2024 compared to $35,768,000 in 2023[494]. - The Phase 3 registrational program for pemvidutide is expected to enroll approximately 5,000 subjects across four trials, evaluating doses of 1.2 mg, 1.8 mg, and 2.4 mg[474]. - Pemvidutide demonstrated a reduction in liver fat content by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, in a Phase 1b trial[475]. - The Phase 2b trial for pemvidutide in MASH is expected to provide top-line data in the second quarter of 2025[476]. - The company discontinued the development of HepTcell after the Phase 2 trial was deemed insufficient for further advancement[482]. Cash Flow and Liquidity - As of December 31, 2024, the company had $131.9 million in cash, cash equivalents, restricted cash, and short-term investments, which is deemed sufficient to fund operations for at least the next twelve months[501]. - Cash and cash equivalents decreased to $36.9 million as of December 31, 2024, from $135.2 million at the end of 2023, a decline of 72.7%[539]. - Net cash used in operating activities was $79.8 million in 2024, an increase of $4.0 million from $75.8 million in 2023, primarily due to a $16.8 million increase in net loss[506]. - Net cash used in investing activities was $28.4 million in 2024, compared to a net cash provided of $13.7 million in 2023, largely due to $115.7 million in purchases of short-term investments[507]. - Net cash provided by financing activities was $10.0 million in 2024, a significant decrease from $86.1 million in 2023, primarily from the issuance of common stock[508]. Equity and Financing - The company raised approximately $96.6 million in net proceeds from at-the-market offerings since inception through December 31, 2024[504]. - The company plans to continue pursuing additional equity or debt financing to address long-term capital needs, including planned clinical trials[511]. - Proceeds from issuance of common stock in at-the-market offerings, net, were $10.0 million in 2024, down from $86.6 million in 2023[543]. - The Company has financed its operations through the issuance of common and preferred stock, long-term debt, and proceeds from research grants and government contracts[545]. - The Company has U.S. federal net operating loss carryforwards of approximately $186.6 million as of December 31, 2024[631]. Assets and Liabilities - Total assets decreased to $139.3 million in 2024, down 33.8% from $210.6 million in 2023[539]. - Total liabilities decreased slightly to $15.8 million in 2024, compared to $16.5 million in 2023[539]. - Stockholders' equity decreased to $123.5 million in 2024, down 36.4% from $194.1 million in 2023[539]. - Total accrued research and development expenses were $6.4 million as of December 31, 2024, with prepaid expenses and other current assets at $2.2 million[534]. - Noncurrent liabilities rose to $5.330 million in 2024 from $4.398 million in 2023, primarily due to an increase in long-term lease obligations[599]. Stock-Based Compensation - Total stock-based compensation expense for the year ended December 31, 2024 was $14.393 million, compared to $10.640 million for 2023[626]. - The total intrinsic value of stock options exercised in 2024 was $1.1 million, compared to $0.2 million in 2023[616]. - As of December 31, 2024, there was $17.5 million of unrecognized compensation cost related to stock options, expected to be recognized over a weighted-average period of 2.5 years[618]. - The Company granted 559,600 shares of Restricted Stock Units (RSUs) with a weighted-average grant date fair value of $9.05 per share during the year ended December 31, 2023[619]. - As of December 31, 2024, total unrecognized compensation expense related to RSUs was $5.4 million, expected to be recognized over approximately 2.5 years[620]. Legal and Regulatory Matters - A class action complaint was filed against the Company on May 6, 2024, alleging violations of the Securities Exchange Act of 1934[645]. - There are ongoing shareholder derivative complaints against the Company's executive officers and board members, alleging breaches of fiduciary duty and other claims[646]. - The derivative actions were consolidated and later dismissed without prejudice on February 3, 2025[646]. - The Company is involved in various contracts and disputes, but none are currently expected to result in material loss[647]. Company Overview - Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and metabolic diseases, with its lead product candidate pemvidutide currently in clinical development[545]. - The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH[648]. - The Company has not generated any revenue from the sale of any products to date[648]. - The Chief Executive Officer is the chief operating decision maker, assessing performance based on net (loss) income[649].

Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patric ...

Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Exhibit 99.1 Altimmune Announces Fourth Quart ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Dir ...

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Na ...